T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.
暂无分享,去创建一个
Yaniv Ziv | M. Schwartz | J. Kipnis | H. Cohen | M. Cardon
[1] P. Linton,et al. Age-related changes in lymphocyte development and function , 2004, Nature Immunology.
[2] I. Whishaw,et al. Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat , 2004, Psychopharmacology.
[3] P. Fletcher,et al. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia , 2003, Schizophrenia Research.
[4] M. Sela,et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Chi,et al. Gene expression profile analyses of cortical dysplasia by cDNA arrays , 2003, Epilepsy Research.
[6] P. Emson,et al. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[7] M. Schwartz,et al. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. , 2003, Investigative ophthalmology & visual science.
[8] M. Koch,et al. Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. , 2003, Current molecular medicine.
[9] M. Egan,et al. Schizophrenia, III: brain-derived neurotropic factor and genetic risk. , 2003, The American journal of psychiatry.
[10] E. D. Kloet,et al. Hormones, brain and stress , 2003 .
[11] M. Schwartz,et al. Protective autoimmunity against the enemy within: fighting glutamate toxicity , 2003, Trends in Neurosciences.
[12] S. Akselrod,et al. Therapeutic vaccination for closed head injury. , 2003, Journal of neurotrauma.
[13] K. Vogeley,et al. Influence of genetic loading, obstetric complications and premorbid adjustment on brain morphology in schizophrenia: , 2003, European Archives of Psychiatry and Clinical Neuroscience.
[14] E. Yoles,et al. Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Hohlfeld,et al. Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases , 2003, Annals of neurology.
[16] P. Jansen-Dürr,et al. A Darwinian-evolutionary concept of age-related diseases , 2003, Experimental Gerontology.
[17] J. Kleinman,et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia , 2003, Molecular Psychiatry.
[18] A. Bassett,et al. Fine Mapping of the Schizophrenia Susceptibility Locus on Chromosome 1q22 , 2003, Human Heredity.
[19] H. Wekerle. Immune protection of the brain--efficient and delicate. , 2002, The Journal of infectious diseases.
[20] Michal Schwartz,et al. Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] R. Hohlfeld,et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.
[22] Michal Schwartz,et al. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. , 2002, Trends in molecular medicine.
[23] A. Meshorer,et al. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system , 2002, Journal of Neuroimmunology.
[24] J. Meador-Woodruff,et al. Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder , 2002, Neuropsychopharmacology.
[25] N. Farber,et al. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity , 2002, Molecular Psychiatry.
[26] Hadas Schori,et al. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system , 2001, Journal of Neuroimmunology.
[27] A. Miller,et al. The neuroimmunology of stress and depression. , 2001, Seminars in clinical neuropsychiatry.
[28] C. Tamminga,et al. Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.
[29] E. Hauben,et al. Neuronal Survival after CNS Insult Is Determined by a Genetically Encoded Autoimmune Response , 2001, The Journal of Neuroscience.
[30] M. Schwartz,et al. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. , 2001, Trends in molecular medicine.
[31] H. Weiner,et al. Protective Autoimmunity Is a Physiological Response to CNS Trauma , 2001, The Journal of Neuroscience.
[32] J. Lieberman,et al. Longitudinal study of brain morphology in first episode schizophrenia , 2001, Biological Psychiatry.
[33] L A Wheeler,et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] S. Deutsch,et al. A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications , 2001, Clinical neuropharmacology.
[35] Hadas Schori,et al. Vaccination for Neuroprotection in the Mouse Optic Nerve: Implications for Optic Neuropathies , 2001, The Journal of Neuroscience.
[36] D. Holtzman,et al. BDNF Protects the Neonatal Brain from Hypoxic-Ischemic InjuryIn Vivo via the ERK Pathway , 2000, The Journal of Neuroscience.
[37] M. Schwartz,et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[38] D. Javitt. Treatment of negative and cognitive symptoms , 1999, Current psychiatry reports.
[39] J. Pierri,et al. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia , 1999, Biological Psychiatry.
[40] S. Ögren,et al. A Behavioral Analysis of the Spatial Learning Deficit Induced by the NMDA Receptor Antagonist MK-801 (Dizocilpine) in the Rat , 1999, Neuropsychopharmacology.
[41] T. Nabeshima,et al. Characterization of learning and memory deficits in C57BL/6 mice infected with LP-BM5, a murine model of AIDS , 1999, Journal of Neuroimmunology.
[42] C. Pantelis,et al. Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. , 1999, Archives of general psychiatry.
[43] Irun R. Cohen,et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.
[44] D. Hu,et al. Effects of MK-801 on vicarious trial-and-error and reversal of olfactory discrimination learning in weanling rats , 1998, Behavioural Brain Research.
[45] G. Weber-Luxenburger,et al. Psychic trauma causing grossly reduced brain metabolism and cognitive deterioration , 1998, Neuropsychologia.
[46] H. Amital,et al. Autoimmunity and schizophrenia: an epiphenomenon or an etiology? , 1993, Israel journal of medical sciences.